Modern options for presbyopia correction in patients with COVID-19
Автор: Vladimirova Yu.V.
Журнал: Международный журнал гуманитарных и естественных наук @intjournal
Статья в выпуске: 7-3 (70), 2022 года.
Бесплатный доступ
This review discusses current options of pharmacotherapy in the treatment of patients with age-related refractive disorder - presbyopia - combined with COVID-19 viral infection. Various treatment options are currently being developed to correct presbyopia, but all of them involve either eyeglass correction, or surgical intervention with application of intraocular lenses. Drug therapy in this case is preferable, since it is less cost-effective, and patients comply more readily to this type of treatment. The application of myotics for presbyopia correction, as well as the combinations of myotics and other drugs for additive treatments and side effects reduction are well documented; however, there is no sufficient data on the results of such treatment. Currently, pyrenoxine, being a component of Catalin-eye drops, has been studied in this regard. It prevents the appearance of quinoid compounds in the lens, which lead to a decreased lens elasticity and, accordingly, to the development of presbyopia. The use of Catalin-eye drops in patients with COVID-19 is especially relevant, since this virus appears to be a predictor of metabolic disorders development. It is necessary to further study Pyrenoxine as a substance that effectively reduces risks of presbyopia development.
Presbyopia, quinoid compounds, drug treatment, pyrenoxine, myotics
Короткий адрес: https://sciup.org/170195177
IDR: 170195177 | DOI: 10.24412/2500-1000-2022-7-3-56-59
Список литературы Modern options for presbyopia correction in patients with COVID-19
- Frick, K. D., Joy, S. M., Wilson, D. A., Naidoo, K. S. & Holden, B. A. The global burden of potential productivity loss from uncorrected presbyopia. Ophthalmology 122, 1706-1710, doi:10.1016/j.ophtha.2015.04.014 (2015).
- Holden, B.A. et al. Global vision impairment due to uncorrected presbyopia. Archives of ophthalmology 126, 1731-1739, doi:10.1001/archopht.126.12.1731 (2008)
- Harrison, L. The FDA approves eye drops for presbyopia. Available online: https://www.medscape.com/viewarticle/961999#vp_2 (accessed November 11, 2021).
- Vuity Ophthalmic (eye) User reviews and ratings: efficiency, ease of use, and satisfaction. Available online: https://www.webmd.com/drugs/drugreview-182672-vuity-ophthalmic-eye (accessed January 20, 2022).
- Tsuneyoshi Y., Higuchi A., Negishi K., Tsubota K. Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy. Sci Rep. 2020;10(1):6757. doi: 10.1038/s41598-020-62436-7.
- Sun X, Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, Yu H. The infection evidence of SARS-CoV-2 in ocular surface: a single-center cross-sectional study. MedRxiv. 2020. doi:10.1101/2020.02.26.20027938.
- Kazuno Negishi, Masahiko Ayaki. Presbyopia developed earlier during the COVID-19 pandemic. November 11, 2021. https://doi.org/10.1371/journal.pone.0259142
- Kovalevskaya M.A. et al. Modern concepts and perspectives of impact on cataractogenesis // Clinical ophthalmology. - 2021. - Vol. 21. - №1. https://doi.org/10.32364/2311-7729-2021-21-1-24-28.
- Kovalevskaya M.A., et al. "What to do if You Need to Postpone the Surgical Treatment of Cataracts in Covid-19". Acta Scientific Ophthalmology Special Issue 1 (2021): 10-13.
- Polunin, G. S., Makarova, I. A. & Bubnova, I. A. [efficacy of catalin eyed drops in age-related cataract agents]. Vestnik oftalmologii 126, 36-39 (2010).
- Grewal, D. S., Brar, G. S. & Grewal, S. P. Correlation of nuclear cataract lens density using scheimpflug images with lens opacities classification system iii and visual function. Ophthalmology 116, 1436-1443, doi:10.1016/j.ophtha.2009.03.002 (2009).
- Teramoto, W., Tao, K., Sekiyama, K. & Mori, S. Reading performance in middle-aged adults with declines in accommodation. Attention, perception & psychophysics 74, 1722-1731, doi:10.3758/s13414-012-0360-6 (2012).
- Dashina V. V., Porkhanov V. A., Malyshev A.V., et al. Effectiveness of prevention of cataract development after vitrectomy in patients with epiretinal membrane. Ophthalmology. 2020;17(4):811-816. https://doi.org/10.18008/1816-5095-2020-4-811-816 [Dashina V. V., Porkhanov V. A., Malyshev A.V., et al. The effectiveness of prevention of cataract development after vitrectomy in patients with epiretinal membrane. Ophthalmology. 2020;17(4):811-816. https://doi.org/10.18008/1816-5095-2020-4-811-816]
- Kociecki J., Krzysztof Zalecki, J Wasiewicz-Rager et al. Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract // Klinika oczna. - 2004. - T. 106. - № 6. - With. 778. doi: 106(6):778-82.
